Well Done LLC Has $509,000 Holdings in Pfizer Inc. (NYSE:PFE)



Well Done LLC cut its stake in Pfizer Inc. (NYSE:PFE – Get Rating) by 8.8% in the first quarter, HoldingsChannel reports. The institutional investor owned 9,826 shares of the biopharmaceutical company’s stock after selling 952 shares during the quarter. Well Done LLC’s holdings in Pfizer were worth $509,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of PFE. Ullmann Wealth Partners Group LLC increased its holdings in Pfizer by 6.2% during the 1st quarter. Ullmann Wealth Partners Group LLC now owns 5,759 shares of the biopharmaceutical company’s stock valued at $298,000 after purchasing an additional 335 shares in the last quarter. Colonial River Wealth Management LLC increased its holdings in Pfizer by 52.3% during the 1st quarter. Colonial River Wealth Management LLC now owns 20,988 shares of the biopharmaceutical company’s stock valued at $1,087,000 after purchasing an additional 7,206 shares in the last quarter. Annex Advisory Services LLC increased its holdings in Pfizer by 23.6% during the 1st quarter. Annex Advisory Services LLC now owns 10,279 shares of the biopharmaceutical company’s stock valued at $532,000 after purchasing an additional 1,966 shares in the last quarter. Northcape Wealth Management LLC increased its holdings in Pfizer by 27.2% during the 1st quarter. Northcape Wealth Management LLC now owns 41,580 shares of the biopharmaceutical company’s stock valued at $2,153,000 after purchasing an additional 8,880 shares in the last quarter. Finally, Redpoint Investment Management Pty Ltd increased its holdings in Pfizer by 9.4% during the 1st quarter. Redpoint Investment Management Pty Ltd now owns 141,914 shares of the biopharmaceutical company’s stock valued at $7,347,000 after purchasing an additional 12,238 shares in the last quarter. 66.50% of the stock is owned by institutional investors and hedge funds.

NYSE:PFE opened at $52.31 on Monday. The firm has a market capitalization of $293.51 billion, a P/E ratio of 12.00, a P/E/G ratio of 0.64 and a beta of 0.73. Pfizer Inc. has a 12-month low of $38.93 and a 12-month high of $61.71. The company has a quick ratio of 1.13, a current ratio of 1.39 and a debt-to-equity ratio of 0.43. The stock’s fifty day simple moving average is $50.66 and its 200-day simple moving average is $52.03.

Pfizer (NYSE:PFE – Get Rating) last issued its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 EPS for the quarter, missing the consensus estimate of $1.66 by ($0.04). The business had revenue of $25.66 billion for the quarter, compared to analyst estimates of $24.73 billion. Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The business’s quarterly revenue was up 76.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.93 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 6.63 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Wednesday, June 29th will be paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 3.06%. The ex-dividend date is Thursday, July 28th. Pfizer’s payout ratio is presently 36.70%.

A number of equities research analysts recently weighed in on PFE shares. JPMorgan Chase & Co. set a $57.00 price target on Pfizer in a report on Tuesday, June 28th. Morgan Stanley initiated coverage on Pfizer in a research report on Wednesday, April 6th. They issued an “equal weight” rating and a $55.00 price objective on the stock. Wells Fargo & Company decreased their objective price on Pfizer from $60.00 to $55.00 in a research report on Wednesday, May 4th. Barclays set a $52.00 price objective on Pfizer in a research report on Monday, June 27th. Finally, Berenberg Bank set a $50.00 price objective on Pfizer in a research report on Friday, May 27th. Nine analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $57.26.

In other Pfizer news, SVP Jennifer B. Damico sold 4,000 shares of Pfizer stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $50.50, for a total value of $202,000.00. Following the sale, the senior vice president now owns 15,064 shares of the company’s stock, valued at approximately $760,732. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of Pfizer stock in a transaction dated Thursday, May 12th. The shares were sold at an average price of $50.00, for a total value of $1,645,400.00. Following the completion of the sale, the executive vice president now directly owns 38,146 shares in the company, valued at approximately $1,907,300. The disclosure for this sale can be found here. Insiders have sold a total of 41,126 shares of company stock worth $2,075,003 in the last ninety days. 0.05% of the stock is currently owned by company insiders.

Pfizer Profile (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)



Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.

.

Leave a Comment